
Enzymatica Q4 2022 - Lower than our estimates

Redeye provides an update in relation to Enzymatica's Q4 2022 report. The year did not live up to our expectations, with total sales of SEK48.9m (SEK57.2m), which can be compared to our sales estimate of SEK56.8m. The Covid-19 pandemic still affects the company; however, we believe 2023 will be a better year overall. We have made some changes in our estimates for the following years, which results in a new fair value range, including a decrease in our base case of SEK6.5 (7).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Enzymatica Q4 2022 - Lower than our estimates